SIRPA and neoplasm: Thus, our study revealed several tumor cell-intrinsic mechanisms underlying the resistance/efficacy of CD47-SIRPα ICB, and provided strategies to overcome resistance or enhance efficacy, shedding light on the clinical development of CD47-SIRPα ICB.